Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2386]

ESMO 2016: MEK inhibition in KRAS-mutant NSCLC did not improve survival

ESMO 2016: MEK inhibition in KRAS-mutant NSCLC did not improve survival

ESMO 2016: Immunotherapy shows promising results in first and second line treatment of metastatic bladder cancer

ESMO 2016: Immunotherapy shows promising results in first and second line treatment of metastatic bladder cancer

ESMO 2016: Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

ESMO 2016: Ipilimumab as adjuvant therapy improves overall survival in high risk stage III melanoma

HDAC inhibitors show promise against cancer stem cells

HDAC inhibitors show promise against cancer stem cells

$ASTRO 2016: Hypofractionated radiotherapy for prostate cancer can reduce treatment time by one-third with comparable QOL$

ASTRO 2016: Hypofractionated radiotherapy for prostate cancer can reduce treatment time by one-third with...

ASTRO 2016: Intermediate risk prostate cancer may be well controlled with brachytherapy alone

ASTRO 2016: Intermediate risk prostate cancer may be well controlled with brachytherapy alone

$ASTRO 2016: Promising toxicity results for intermediate risk prostate cancer patients undergoing extreme hypofractionation$

ASTRO 2016: Promising toxicity results for intermediate risk prostate cancer patients undergoing extreme...

Nationwide study sets benchmarks for 30-day mortality following chemotherapy for breast and lung cancer in England

Nationwide study sets benchmarks for 30-day mortality following chemotherapy for breast and lung cancer in England

Nebivolol prevents anthracycline-induced cardiotoxicity

Nebivolol prevents anthracycline-induced cardiotoxicity

Peptide mutants may help to identify vulnerability in tumour cells

Peptide mutants may help to identify vulnerability in tumour cells

More from ecancer